Cladribine Shows a Robust Safety Profile – Both as First-Line and Subsequent Therapy in MS
There is limited knowledge regarding the specific effects of cladribine on the immune system in patients with multiple sclerosis (MS). Cladribine, a purine analogue and immunomodulatory agent whose active metabolite accumulates intracellularly, inhibits DNA synthesis and induces apoptosis, predominantly in lymphocytes. New data presented at ESMO 2025 demonstrate that cladribine exhibits a robust safety profile, both as a first-line treatment and as a subsequent therapy in MS.
Relateret indhold
Brænder du for at skrive?
Vil du gerne dele din forskning eller dine kliniske erfaringer med dine kollegaer inden for netop dit speciale? Har du en ide til en artikel, som du gerne vil udgive hos os? Send redaktionen en mail på redaktion@bpno.dk
Send mail til redaktionen